Long-term follow-up of people treated with Kymriah for blood cancers
Follows people with B-cell leukemia or lymphoma treated with Kymriah over time.
Key facts
- Who runs it
- Novartis Pharmaceuticals
- Where
- Bundang Gu, Busan, Gyeonggi-do, Incheon, Jeollanam, Seongnam-si, Seoul, and Ulsan, South KoreaSee the 8 sites
- Trial code
- Registry title
- Long-term Follow up Local Registry Study of Kymriah in South Korea
- Status
- Recruiting
- People taking part
- 500 people, planned
- Started
- 12 Mar 2025
- Expected to end
- 30 Dec 2039
- Type of study
- Observational
- Treatments tested
- Tisagenlecleucel
- Record updated
- 30 July 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with B-cell blood cancers who received tisagenlecleucel (Kymriah) in routine care in South Korea. It follows them over time to check long-term safety.
- Age
- 0 to 100 years
- Sex
- All sexes can join.
- Disease stage
- B-cell acute lymphoblastic leukemia, diffuse large B-cell lymphoma or follicular lymphoma.
- Earlier treatment
- Must have received a tisagenlecleucel infusion in the commercial setting, a managed access program or another pathway.
Main reasons for not taking part
- Already in, or going to be in, the Novartis long-term follow-up protocol CCTL019A2205B
- Has not consented to data collection
The registry criteria, word for word
Show all 3 criteriaShow less
Who can take part
- Patients who receive tisagenlecleucel infusion in the commercial setting, treated under a managed access program or other pathway, e.g., when product was manufactured for the commercial setting but turned out to be out of specification (OOS)
- Consented to data collection
Who cannot take part
- Patients who are enrolled or will be enrolled in the Novartis long term follow-up protocol CCTL019A2205B
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 0 and 100 years old?
Where in South Korea
- Bundang Gu, Gyeonggi-doHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
- BusanHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
- Gyeonggi-do, KoreaHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
- IncheonHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
- JeollanamHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
- Seongnam-si, Gyeonggi-doHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
- Seoul, KoreaHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
- UlsanHospital not named in the registryContact: Novartis PharmaceuticalsTaking people
About the trial
What the trial wants to find out
This study is multicenter, primary data collection, non-interventional registry study to assess long-term safety, secondary malignancy risk, and effectiveness of tisagenlecleucel in patients with B-cell malignancies in a routine clinical practice setting in Korea.
The group in the trial
- Tisagenlecleucel
Patients who have been treated with tisagenlecleucel
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Registry to Assess Long-Term Safety of Patients With B-Lymphocyte Malignancies Treated With Tisagenlecleucel in South Korea
- Plain-language title
- Long-term follow-up of people treated with Kymriah for blood cancersGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06785818, who can take part
- Record updated
- 30 July 2026